stockrowGuardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) EBITDA
Guardant Health, Inc.'s EBITDA for fiscal 2025 was −$403.4M, compared with −$408.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$444.9M. Over the past ten years it has ranged from −$535.4M (fiscal 2023) to −$39.9M (fiscal 2016); the current reading is higher than 40% of that period. Guardant Health, Inc. ranks 49th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$403.4M | — |
| FY2024 | −$408.0M | — |
| FY2023 | −$535.4M | — |
| FY2022 | −$501.3M | — |
| FY2021 | −$373.3M | — |
| FY2020 | −$230.1M | — |
| FY2019 | −$73.3M | — |
| FY2018 | −$86.2M | — |
| FY2017 | −$71.0M | — |
| FY2016 | −$39.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$120.6M | — |
| Mar 2026 | −$118.9M | — |
| Dec 2025 | −$116.6M | — |
| Sep 2025 | −$88.8M | — |
| 31 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $2.3B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| ICLR ICON PLC compare | $1.1B |
| RVTY Revvity Inc. compare | $775.8M |
| MEDP Medpace Holdings, Inc. compare | $634.5M |
| CRL Charles River Laboratories International, Inc. compare | $553.0M |
| GH Guardant Health, Inc. | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GH
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement